5 ANNEX V COMMON SPECIFICATIONS FOR DEVICES INTENDED FOR DETECTION OR QUANTIFICATION OF MARKERS OF HEPATITIS C VIRUS (HCV) INFECTION, Regulation (EU) 2022/1107

In forcesince 4 Jul 2022

This Annex applies to devices intended for detection or quantification of markers of hepatitis C virus (HCV) infection.

Table 1 applies to first-line assays for anti-HCV antibodies (anti-HCV) and combined antigen/antibody tests for HCV (HCV Ag/Ab) which are not rapid tests.

Table 2 applies to first-line assays for anti-HCV and HCV Ag/Ab which are rapid tests.

Table 3 applies to confirmatory and supplemental assays for anti-HCV.

Table 4 applies to HCV antigen tests and HCV Ag/Ab.

Table 5 applies to qualitative and quantitative NAT devices for HCV RNA.

Table 6 applies to HCV self-tests.

[Blood donor populations shall be investigated from at least two blood donation centres and consist of consecutive blood donations, which have not been selected to exclude first-time donors.]

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥400

Including specimens from different stages of infection and reflecting different antibody patterns

HCV genotype 1-4: > 20 specimens per genotype (including non-a subtypes of genotype 4); HCV genotypes 5 and 6: > 5 specimens each;

including 25 positive ‘same day’ fresh serum specimens (≤ 1 day after specimen taking)

all true positive specimens shall be identified as positive

Seroconversion panels |

≥30 panels

HCV seroconversion panels for the evaluation of HCV antigen and antibody combined tests (HCV Ag/Ab) shall start with one or more negative bleeds and comprise panel members from early HCV infection (HCV core antigen and/or HCV RNA positive but anti-HCV negative).

diagnostic sensitivity during seroconversion shall represent the state of the art

HCV Ag/Ab tests shall demonstrate enhanced sensitivity in early HCV infection when compared to HCV antibody only tests.

Diagnostic specificity | Unselected blood donors (including first-time donors) | ≥5000 | ≥99,5%

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens |

≥100 in total

(e.g. RF+, from related virus infections, from pregnant women)

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥400

including specimens from different stages of infection and reflecting different antibody patterns.

HCV genotype 1-4: > 20 specimens per genotype (including non-a subtypes of genotype 4); HCV genotypes 5 and 6: > 5 specimens each;

all true positive specimens shall be identified as positive

Seroconversion panels |

≥30 panels

HCV seroconversion panels for the evaluation of HCV antigen and antibody combined tests (HCV Ag/Ab) shall start with one or more negative bleeds and comprise panel members from early HCV infection (HCV core antigen and/or HCV RNA positive but anti-HCV negative).

diagnostic sensitivity during seroconversion shall represent the state of the art

HCV Ag/Ab tests shall demonstrate enhanced sensitivity in early HCV infection when compared to HCV antibody only tests.

Diagnostic specificity | Unselected blood donors (including first-time donors)1 | ≥1000 | ≥ 99 %

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens |

≥200 specimens from pregnant women

≥100 other potentially cross-reacting specimens in total (e.g. RF+, from related infections)

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥300

Including specimens from different stages of infection and reflecting different antibody patterns.

HCV genotypes 1 – 4: > 20 specimens (including non-a subtypes of genotype 4; HCV genotype 5: > 5 specimens; HCV genotype 6: as far as available

identification as “confirmed positive” or “indeterminate”, not as “negative”

Seroconversion panels | ≥15 seroconversion panels/low titre panels | diagnostic sensitivity during seroconversion shall represent the state of the art

Diagnostic specificity | Blood donors | ≥200 | No false positive results/ no neutralisation

Hospitalised patients | ≥200

Cross-reactivity | Potentially cross-reacting specimens | ≥50 in total (including specimens from pregnant women, specimens with indeterminate results in other confirmatory assays)

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Diagnostic sensitivity | Positive specimens | ≥25 HCV core antigen and/or HCV RNA positive but anti-HCV negative specimens, comprising HCV genotypes 1-6 (if a genotype is not available, a justification shall be made) | all true positive specimens shall be identified as positive

Seroconversion panels |

≥20 seroconversion panels/low titre panels

HCV seroconversion panels for the evaluation of HCV antigen and antibody combined tests shall start with one or more negative bleeds and comprise panel members from early HCV infection (HCV core antigen and/or HCV RNA positive but anti-HCV negative).

diagnostic sensitivity during seroconversion shall represent the state of the art

HCV antigen and antibody combined tests shall demonstrate enhanced sensitivity in early HCV infection when compared to HCV antibody only tests.

Analytical sensitivity | WHO International Standard HCV core (PEI 129096/12) | Dilution series |

Diagnostic specificity | Blood donors | ≥200 | ≥ 99,5 % after neutralisation or, if no neutralisation test available, after resolution of the specimen status

Hospitalised patients | ≥200 | Potential limitations for specificity, if any, shall be identified

Cross-reactivity | Potentially cross-reacting specimens | ≥50

1.

For target sequence amplification devices, a functionality control for each specimen (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.

2.

Genotype and/or subtype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped specimens.

3.

Potential cross-reactivity of non-target nucleic acid sequences shall be analysed by appropriate primer or probe design validation and shall also be validated by testing selected specimens.

4.

Results of quantitative NAT devices shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.

[Reference: European Pharmacopeia 9.0, 2.6.21 Nucleic acid amplification techniques, Validation.]

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Analytical sensitivity | WHO International Standard HCV RNA(or calibrated reference materials) |

NAT sensitivity and NAT LOD shall be validated by dilution series of reference materials, testing of replicates (minimum 24) at different analyte concentrations, including those with transition from positive to negative results with the respective NAT device.

LOD shall be expressed as 95% positive cut-off value (IU/ml) after statistical analysis (e.g. Probit).

quantitative NAT: definition of lower, upper quantification limit, precision, accuracy,

‘linear’ measuring range, ‘dynamic range’.

Reproducibility at different concentration levels

According to the state of the art

HCV genotype sensitivity |

all relevant genotypes/subtypes, preferably from international reference materials

potential substitutes for rare HCV genotypes (to be quantified by appropriate methods): in vitro transcripts; plasmids

Qualitative NAT: ≥10 specimens/genotype or subtype

Quantitative NAT: dilution series for demonstration of quantification efficiencies

According to the state of the art

Diagnostic sensitivity | Positive specimens reflecting the routine conditions of users (e.g. no pre-selection of specimens) |

Quantitative NAT: ≥100

Comparative results with another NAT system shall be generated in parallel

According to the state of the art

Seroconversion panels |

Qualitative NAT: ≥10 panels

Comparative results with another NAT system shall be generated in parallel

According to the state of the art

Diagnostic specificity | Blood donor specimens |

Qualitative NAT: ≥500

Quantitative NAT: ≥100

According to the state of the art

Cross-reactivity | Potentially cross-reacting specimens | >10 human flavivirus (e.g. HGV, YFV) positive specimens | According to the state of the art

Carry-over |

High HCV RNA positive;

HCV RNA negative

At least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The virus titres of the high positive specimens shall be representative of high virus titres occurring naturally. | According to the state of the art

Detection in relation to antibody status | HCV RNA positives: anti-HCV negative, anti-HCV positive | Pre-seroconversion (anti-HCV negative) and post-seroconversion (anti-HCV positive) specimens | According to the state of the art

Whole system failure rate | HCV RNA low-positive | ≥100 HCV RNA low-positive specimens shall be tested. These specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration. | ≥99% positive

[For each body fluid claimed for use with the device, e.g. whole blood, urine, saliva, etc., the sensitivity and specificity of the device for self-testing in the hands of lay persons shall be defined against the confirmed patient infectious status.] [The result interpretation study shall include reading and interpretation of the test results by at least 100 lay persons with each lay person subjected to reading results covering the specified range of result reactivity levels. The manufacturer shall determine the concordance between lay person reading and professional user reading.] [Tests shall be performed prior to the result interpretation study using whenever possible the specimen type intended by the manufacturer. The tests may be performed on contrived specimens based on the natural matrix of the respective specimen type.] [A higher proportion of the specimens shall be in the weak-positive range close to the cut-off or LOD of the test.]

Performance characteristic | Specimens | Number of lay persons

Result interpretation |

Interpretation of results by lay persons reflecting the following range of reactivity levels:

non-reactive

reactive

weak reactive

invalid

≥ 100

Diagnostic sensitivity | lay persons that are known positive | ≥ 200

Diagnostic specificity | lay persons that do not know their status | ≥ 400

lay persons that are at high risk of acquiring the infection | ≥ 200